Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation

Annals of Surgical Oncology

Volumn 20, Issue 3 SUPPL., 2013, Pages

  Sofocleous, Constantinos T ^a   Garg, Sandeep K ^a   Cohen, Perry ^a   Petre, Elena N ^a   Gonen, Mithat ^a   Erinjeri, Joseph P ^a   Downey, Robert J ^a   Travis, William D ^a   Solomon, Stephen B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; KI 67 ANTIGEN; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RISK; CANCER SPECIFIC SURVIVAL; CLINICAL ARTICLE; DEATH; DISEASE SPECIFIC SURVIVAL; ELECTRODE; FEMALE; HAZARD RATIO; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL RECURRENCE FREE SURVIVAL; LUNG TUMOR; MALE; MIDDLE AGED; NECROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RISK; TUMOR ABLATION; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT; ADENOCARCINOMA; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CATHETER ABLATION; CELL PROLIFERATION; COLORECTAL NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ENZYME IMMUNOASSAY; FOLLOW UP; LUNG NEOPLASMS; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIATION DOSE; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CATHETER ABLATION; CELL PROLIFERATION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84892792727     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3140-1     Document Type: Article

References (37)

1. Lencioni R, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008;9:621-8.
2. Pua BB, Solomon SB. Radiofrequency ablation of primary and metastatic lung cancers. Semin Ultrasound CT MR. 2009;30: 113-24.
3. Crocetti L, Lencioni R. Radiofrequency ablation of pulmonary tumors. Eur J Radiol. 2010;75:23-7.
4. Thanos L, Mylona S, Ptohis N, Tsiouris S, Sotiropoulou E, Pomoni A, et al. Percutaneous radiofrequency thermal ablation in the management of lung tumors: presentation of clinical experience on a series of 35 patients. Diagn Interv Radiol. 2009;15: 290-6.
5. Simon CJ, Dupuy DE, DiPetrillo TA, Safran HP, Grieco CA, Ng T, et al. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology. 2007;243:268-75.
6. Hess A, Palussiere J, Goyers JF, Guth A, Auperin A, de Baere T. Pulmonary radiofrequency ablation in patients with a single lung: feasibility, efficacy, and tolerance. Radiology. 2011;258:635-42.
7. Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H. Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol. 2000;174:57-9.
8. Yasui K, Kanazawa S, Sano Y, Fujiwara T, Kagawa S, Mimura H, et al. Thoracic tumors treated with CT-guided radiofrequency ablation: initial experience. Radiology. 2004;231:850-7.
9. Akeboshi M, Yamakado K, Nakatsuka A, Hataji O, Taguchi O, Takao M, et al. Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response. J Vasc Interv Radiol. 2004;15:463-70.
10. Sonntag PD, Hinshaw JL, Lubner MG, Brace CL, Lee FT, Jr. Thermal ablation of lung tumors. Surg Oncol Clin N Am. 2011; 20:369-87, ix.
11. Yamagami T, Kato T, Hirota T, Yoshimatsu R, Matsumoto T, Shimada J, et al. Risk factors for occurrence of local tumor progression after percutaneous radiofrequency ablation for lung neoplasms. Diagn Interv Radiol. 2007;13:199-203.
12. de Baere T, Palussiere J, Auperin A, Hakime A, Abdel-Rehim M, Kind M, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006;240:587-96.
13. Hiraki T, Sakurai J, Tsuda T, Gobara H, Sano Y, Mukai T, et al. Risk factors for local progression after percutaneous radiofrequency ablation of lung tumors: evaluation based on a preliminary review of 342 tumors. Cancer. 2006;107:2873-80.
14. Sofocleous CT, Klein KM, Hubbi B, Brown KT, Weiss SH, Kannarkat G, et al. Histopathologic evaluation of tissue extracted on the radiofrequency probe after ablation of liver tumors: preliminary findings. AJR Am J Roentgenol. 2004;183:209-13.
15. Snoeren N, Jansen MC, Rijken AM, van Hillegersberg R, Slooter G, Klaase J, et al. Assessment of viable tumour tissue attached to needle applicators after local ablation of liver tumours. Dig Surg. 2009;26:56-62.
16. Snoeren N, Huiskens J, Rijken AM, van Hillegersberg R, van Erkel AR, Slooter GD, et al. Viable tumor tissue adherent to needle applicators after local ablation: a risk factor for local tumor progression. Ann Surg Oncol. 2011;18:3702-10.
17. Sofocleous CT, Nascimento RG, Petrovic LM, Klimstra DS, Gonen M, Brown KT, et al. Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. Radiology. 2008;249:364-74.
18. Sofocleous CT, Garg S, Petrovic LM, Gonen M, Petre EN, Klimstra DS, et al. Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies. Ann Surg Oncol. 2012;19:4262-9.
19. Sofocleous CT, May B, Petre EN, Gonen M, Thornton RH, Alago W, et al. Pulmonary thermal ablation in patients with prior pneumonectomy. AJR Am J Roentgenol. 2011;196:W606-12.
20. Sofocleous CT, Sideras P, Petre EN, Solomon SB. Ablation for the management of pulmonary malignancies. AJR Am J Roentgenol. 2011;197:W581-9.
21. Jin GY, Lee JM, Lee YC, Han YM, Lim YS. Primary and secondary lung malignancies treated with percutaneous radiofrequency ablation: evaluation with follow-up helical CT. AJR Am J Roentgenol. 2004;183:1013-20.
22. Gillams A. Lung tumour ablation-where are we now? Cancer Imaging. 2008;8:116-7.
23. Rose SC, Dupuy DE, Gervais DA, Millward SF, Brown DB, Cardella JF, et al. Research reporting standards for percutaneous thermal ablation of lung neoplasms. J Vasc Interv Radiol. 2009; 20:S474-85.
24. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269-90.
25. Yang J, Ramnath N, Moysich KB, Asch HL, Swede H, Alrawi SJ, et al. Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. BMC Cancer. 2006;6:203.
26. King KL, Hwang JJ, Chau GY, Tsay SH, Chi CW, Lee TG, et al. Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 1998;13:273-9.
27. Smith S, Gillams A. Imaging appearances following thermal ablation. Clin Radiol. 2008;63:1-11.
28. Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD 3rd, Dupuy DE, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2009;20:S377-90.
29. Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, et al. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Interact Cardiovasc Thorac Surg. 2010;10:1009-14.
30. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 1989;84:1065-73.
31. R: A language and environment for statistical computing. R Development Core Team; R Foundation for Statistical Computing. Vienna; 2011.
32. Vilar E, Salazar R, Perez-Garcia J, Cortes J, Oberg K, Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007;14: 221-32.
33. Fernandez-Cebrian JM, Nevado Santos M, Vorwald Kuborn P, Pardo de Lama M, Mart?n-Cavanna J, Pacheco Mart?nez P, et al. Can the clinical outcome in stage II colon carcinomas be predicted by determination of molecular marker expression? Clin Transl Oncol. 2007;9:663-70.
34. Clasen S, Krober SM, Kosan B, Aebert H, Fend F, Bomches A, et al. Pathomorphologic evaluation of pulmonary radiofrequency ablation: proof of cell death is characterized by DNA fragmentation and apoptotic bodies. Cancer. 2008;113:3121-9.
35. Jaskolka JD, Kachura JR, Hwang DM, Tsao MS, Waddell TK, Asch MR, et al. Pathologic assessment of radiofrequency ablation of pulmonary metastases. J Vasc Interv Radiol. 2010;21:1689-96.
36. Schneider T, Reuss D, Warth A, Schnabel PA, von Deimling A, Herth FJ, et al. The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms-results of an ablate and resect study. Eur J Cardiothorac Surg. 2011;39:968-73.
37. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-22.